The purpose of this clinical research study is to learn if BMS-587101 is effective on the treatment of Moderate to Severe Psoriasis. The safety of this treatment will also be studied.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
120
Local Institution
Phoenix, Arizona, United States
Local Institution
Tucson, Arizona, United States
Local Institution
San Diego, California, United States
To estimate the clinical response in terms of the percent of subjects achieving PASI_50 in each treatment arm, and to determine whether there was a difference in PASI_50 between each BMS-587101 treatment arm and placebo
To estimate the proportion of patients achieving a PASI 75 response in each treatment arm.
To estimate the percent change (or reduction) in PASI score at 12 weeks of treatment in each treatment arm.
To estimate the proportion of patients achieving a PGA score of clear to minimal in each treatment arm.
To estimate the percent change from baseline in epidermal thickness of psoriatic lesion.
To evaluate the safety and tolerability of BMS-587101 in patients with psoriasis.
To evaluate the single- and multiple-dose pharmacokinetics of BMS-587101
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Local Institution
Miami Beach, Florida, United States
Local Institution
Pinellas Park, Florida, United States
Local Institution
Boise, Idaho, United States
Local Institution
Fridley, Minnesota, United States
Local Institution
St Louis, Missouri, United States
Local Institution
New Brunswick, New Jersey, United States
Local Institution
New York, New York, United States
...and 6 more locations